Artificial intelligence and machine learning are reshaping how investors build and maintain portfolios. These tools bring ...

Amazon Q Developer is a useful AI-powered coding assistant with chat, CLI, Model Context Protocol and agent support, and AWS ...

In this essay by Edgar Calabia Samar, he shows how Eka Kurniawan’s 'Beauty Is a Wound' teaches us to dream at multiple scales ...

I put Gemini 3.0 and Grok 4.1 through 9 head-to-head prompts — from logic and creativity to humor and tone. Here's what happened and how the models each surprised me.

Getting good at LeetCode Java can feel like a puzzle sometimes, right? You see all these problems, and you’re not sure where ...

Writing a check can be done by filling out six lines on the check. There are also alternatives to sending a check. Many, or all, of the products featured on this page are from our advertising partners ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...